+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Novavax Inc - logo

Novavax is a clinical-stage vaccine company that develops recombinant nanoparticle vaccines and adjuvants. The company produces its vaccines using its proprietary recombinant nanoparticle vaccine technology. Its product pipeline includes respiratory syncytial virus (RSV) vaccine candidates for elderly and maternal immunization, seasonal quadrivalent influenza and pandemic H7N9 vaccines, a vaccine candidate against Ebola Virus and others. Founded in 1987, it is headquartered in Gaithersburg, Maryland.

From
From
From
From
From
From
NanoFlu Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

NanoFlu Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
Pandemic Influenza - Global Clinical Trials Review, H2, 2021 - Product Thumbnail Image

Pandemic Influenza - Global Clinical Trials Review, H2, 2021

  • Clinical Trials
  • September 2021
  • 121 Pages
  • Global
From
Seasonal Influenza: Competitive Landscape to 2026 - Product Thumbnail Image

Seasonal Influenza: Competitive Landscape to 2026

  • Report
  • November 2018
  • 49 Pages
  • Global
From
From
From
From
Novavax, Inc. - Company Profile and SWOT Analysis - Product Thumbnail Image

Novavax, Inc. - Company Profile and SWOT Analysis

  • SWOT Analysis
  • April 2025
  • 46 Pages
From
Loading Indicator